Examining visual field defects in the paediatric population exposed to vigabatrin

E L Spencer1, G F A Harding

  • 1Neurosciences Research Institute, Aston University, Birmingham, UK. emma.spencer@quintiles.com

Insights

Vigabatrin, an antiepileptic drug, can cause visual field loss in children. A new field-specific visual evoked potential (VEP) test is effective for detecting this vision defect in pediatric patients.

Area of Science:

  • Ophthalmology
  • Neurology
  • Pediatrics

Background:

  • Vigabatrin is an effective antiepileptic drug for infantile spasms.
  • Vigabatrin use is associated with peripheral visual field loss.
  • Assessing visual field function in children is challenging.

Purpose of the Study:

  • To evaluate a field-specific visual evoked potential (VEP) for detecting vigabatrin-induced visual field defects in children.
  • To compare the VEP method with electroretinography (ERG) and perimetry in a pediatric population.

Main Methods:

  • A field-specific VEP using central and peripheral stimuli was developed.
  • Thirty-nine children (3-15 years) treated with vigabatrin were included.
  • VEP, ERG, and perimetry were performed where feasible.

Main Results:

  • The field-specific VEP showed 75% sensitivity and 85.7% specificity in detecting visual field abnormalities.
  • The VEP correctly identified 3/4 abnormal perimetry results and 6/7 normal perimetry results.
  • 30-Hz flicker amplitude in ERG showed 75% sensitivity and 71% specificity.

Conclusions:

  • The field-specific VEP is a well-tolerated and reliable method for assessing vigabatrin-associated visual field loss in children.
  • The prevalence of this visual defect in children appears similar to that in adults.
  • VEP offers a viable alternative for visual field assessment in pediatric patients unable to complete perimetry.